Market Cap 279.89M
Revenue (ttm) 0.00
Net Income (ttm) -101.70M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.38
Volume 595,700
Avg Vol 916,192
Day's Range N/A - N/A
Shares Out 134.56M
Stochastic %K 74%
Beta 0.41
Analysts Strong Sell
Price Target $4.60

Company Profile

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has collaboration agreement for Evorpacept combination programs comprising Jazz Pharmaceuticals plc for zanidatama...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 466 7125
Address:
323 Allerton Avenue, South San Francisco, United States
maplelakeduckslayer
maplelakeduckslayer May. 9 at 4:23 AM
$ALXO đź’Ş
0 · Reply
MarketBeat
MarketBeat May. 8 at 8:03 PM
ALX Oncology Q1 Earnings Call Highlights $ALXO #ALXOncology #instantalerts #NASDAQ:ALXO https://www.marketbeat.com/instant-alerts/alx-oncol
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 8 at 1:27 PM
$ALXO Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.17 up 70.69% YoY • ALX Oncology Holdings Inc. believes its existing cash, cash equivalents, and investments will enable it to fund operating expenses and capital expenditure requirements through the first half of 2028.
0 · Reply
focafoca99
focafoca99 May. 8 at 12:34 PM
$ALXO detailed its Q1 2026 financial results in a press release.
0 · Reply
MakingMoneyHere
MakingMoneyHere May. 7 at 4:04 PM
$ALXO What the fc is wrong with this stock 🤣
0 · Reply
Gabriel_DS
Gabriel_DS May. 7 at 2:26 PM
$ALXO total BS SP
0 · Reply
JustHereForALXO
JustHereForALXO May. 7 at 1:04 PM
$ALXO Can now predict treatment response based on biomarker levels. Pretty great. I would have thought they had taken this approach a decade ago, but I guess they took CD47 expression as a given. Oh well, better late than never. As long as they only treat patients with the appropriate biomarkers, then their results should look quite good from here on out. Approval and sales here we come.
0 · Reply
Gabriel_DS
Gabriel_DS May. 7 at 12:28 PM
$ALXO https://finance.yahoo.com/sectors/healthcare/articles/alx-oncology-evorpacept-combination-zanidatamab-120000277.html
0 · Reply
SuperGreenToday
SuperGreenToday May. 5 at 5:33 PM
$ALXO Share Price: $1.89 Contract Selected: Nov 20, 2026 $2.0 Calls Buy Zone: $0.26 – $0.32 Target Zone: $0.41 – $0.50 Potential Upside: 53% ROI Time to Expiration: 198 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Iorgi
Iorgi May. 1 at 2:56 PM
$ALXO Breast cancer is a huge deal and this little company is making great progress. Can't wait for what I expext will continue to be good news on May 7th.
0 · Reply
Latest News on ALXO
ALX Oncology Holdings Earnings Call Transcript: Q1 2026

May 8, 2026, 8:30 AM EDT - 4 days ago

ALX Oncology Holdings Earnings Call Transcript: Q1 2026


ALX Oncology initiated with an Overweight at Wells Fargo

2026-03-19T09:55:11.000Z - 7 weeks ago

ALX Oncology initiated with an Overweight at Wells Fargo


ALX Oncology initiated with a Buy at UBS

2026-03-06T13:25:31.000Z - 2 months ago

ALX Oncology initiated with a Buy at UBS


ALX Oncology Holdings Earnings Call Transcript: Q4 2025

Feb 27, 2026, 8:30 AM EST - 2 months ago

ALX Oncology Holdings Earnings Call Transcript: Q4 2025


ALX Oncology price target raised to $4 from $3 at Piper Sandler

2026-02-05T11:51:50.000Z - 3 months ago

ALX Oncology price target raised to $4 from $3 at Piper Sandler


ALX Oncology Announces Pricing of Underwritten Offering

Jan 30, 2026, 8:30 AM EST - 3 months ago

ALX Oncology Announces Pricing of Underwritten Offering


ALX Oncology announces data from Phase 2 trial of evorpacept

2025-12-07T18:35:16.000Z - 5 months ago

ALX Oncology announces data from Phase 2 trial of evorpacept


ALX Oncology to Present at Upcoming Investor Conferences

Nov 18, 2025, 11:00 AM EST - 6 months ago

ALX Oncology to Present at Upcoming Investor Conferences


ALX Oncology initiated with a Buy at Jefferies

2025-11-13T14:35:58.000Z - 6 months ago

ALX Oncology initiated with a Buy at Jefferies


ALX Oncology Holdings Earnings Call Transcript: Q3 2025

Nov 7, 2025, 8:30 AM EST - 6 months ago

ALX Oncology Holdings Earnings Call Transcript: Q3 2025


ALX Oncology appoints Klencke as interim CMO

2025-09-12T12:35:38.000Z - 8 months ago

ALX Oncology appoints Klencke as interim CMO


ALX Oncology doses first patient in Phase 1 trial for ALX2004

2025-08-19T12:10:35.000Z - 9 months ago

ALX Oncology doses first patient in Phase 1 trial for ALX2004


ALX Oncology Holdings Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 9 months ago

ALX Oncology Holdings Earnings Call Transcript: Q2 2025


ALX Oncology price target lowered to $1 from $1.20 at UBS

2025-05-21T11:05:46.000Z - 1 year ago

ALX Oncology price target lowered to $1 from $1.20 at UBS


ALX Oncology Holdings Transcript: Status Update

May 20, 2025, 11:00 AM EDT - 1 year ago

ALX Oncology Holdings Transcript: Status Update


ALX Oncology Holdings Transcript: Status Update

Mar 5, 2025, 9:00 AM EST - 1 year ago

ALX Oncology Holdings Transcript: Status Update


ALX Oncology to Host Virtual R&D Day on March 5, 2025

Feb 18, 2025, 8:00 AM EST - 1 year ago

ALX Oncology to Host Virtual R&D Day on March 5, 2025


ALX Oncology Holdings Transcript: Study Update

Jan 23, 2025, 4:00 PM EST - 1 year ago

ALX Oncology Holdings Transcript: Study Update


ALX Oncology Holdings Transcript: Study Update

Dec 17, 2024, 8:00 AM EST - 1 year ago

ALX Oncology Holdings Transcript: Study Update


ALX Oncology Holdings Transcript: Study Result

Jul 31, 2024, 4:30 PM EDT - 1 year ago

ALX Oncology Holdings Transcript: Study Result


ALX Oncology Holdings Transcript: Study Update

Jun 7, 2024, 1:00 PM EDT - 2 years ago

ALX Oncology Holdings Transcript: Study Update


maplelakeduckslayer
maplelakeduckslayer May. 9 at 4:23 AM
$ALXO đź’Ş
0 · Reply
MarketBeat
MarketBeat May. 8 at 8:03 PM
ALX Oncology Q1 Earnings Call Highlights $ALXO #ALXOncology #instantalerts #NASDAQ:ALXO https://www.marketbeat.com/instant-alerts/alx-oncol
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 8 at 1:27 PM
$ALXO Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.17 up 70.69% YoY • ALX Oncology Holdings Inc. believes its existing cash, cash equivalents, and investments will enable it to fund operating expenses and capital expenditure requirements through the first half of 2028.
0 · Reply
focafoca99
focafoca99 May. 8 at 12:34 PM
$ALXO detailed its Q1 2026 financial results in a press release.
0 · Reply
MakingMoneyHere
MakingMoneyHere May. 7 at 4:04 PM
$ALXO What the fc is wrong with this stock 🤣
0 · Reply
Gabriel_DS
Gabriel_DS May. 7 at 2:26 PM
$ALXO total BS SP
0 · Reply
JustHereForALXO
JustHereForALXO May. 7 at 1:04 PM
$ALXO Can now predict treatment response based on biomarker levels. Pretty great. I would have thought they had taken this approach a decade ago, but I guess they took CD47 expression as a given. Oh well, better late than never. As long as they only treat patients with the appropriate biomarkers, then their results should look quite good from here on out. Approval and sales here we come.
0 · Reply
Gabriel_DS
Gabriel_DS May. 7 at 12:28 PM
$ALXO https://finance.yahoo.com/sectors/healthcare/articles/alx-oncology-evorpacept-combination-zanidatamab-120000277.html
0 · Reply
SuperGreenToday
SuperGreenToday May. 5 at 5:33 PM
$ALXO Share Price: $1.89 Contract Selected: Nov 20, 2026 $2.0 Calls Buy Zone: $0.26 – $0.32 Target Zone: $0.41 – $0.50 Potential Upside: 53% ROI Time to Expiration: 198 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
Iorgi
Iorgi May. 1 at 2:56 PM
$ALXO Breast cancer is a huge deal and this little company is making great progress. Can't wait for what I expext will continue to be good news on May 7th.
0 · Reply
maplelakeduckslayer
maplelakeduckslayer Apr. 24 at 8:09 PM
$ALXO gave that entry right where I wanted it, hammer on the daily high volume doji on the weekly. See how it follows up next week
0 · Reply
maplelakeduckslayer
maplelakeduckslayer Apr. 22 at 6:43 PM
$ALXO have slowly grabbed some of this one back near 1.60 but still hoping it can go back to bottom of wedge near 1.50, which also correlates to the 200 day, for full size
0 · Reply
ko_my_money
ko_my_money Apr. 20 at 4:27 PM
0 · Reply
focafoca99
focafoca99 Apr. 13 at 3:44 PM
$ALXO appointed Jeff Knight as chief financial officer.
0 · Reply
baliosxantos
baliosxantos Apr. 9 at 6:59 PM
0 · Reply
WS86
WS86 Apr. 9 at 6:41 PM
$ALXO What's going on with this today? No news...
0 · Reply
superyin
superyin Mar. 13 at 4:08 PM
$TLRY looking through other tickers in the sector didn't give me much hope—implied volatility for Aurora in June—but it reminded me of another ticker I followed for years, $PETZ—this is a company that kicks the can down the road on its financials every chance it gets: in Sept last year, they announced their annual meeting for last day of Oct; 2 weeks after, they report half of their fiscal year results; it's now March, and they haven't released any other news, this company has basically been running on the fumes of one crackpot genius accountant since COVID, but hell they did numbers Jan 1-Jan 31 this year (30% gain)... I don't trade pennies anymore (except Tilray pre-split), but I have always consider Tilray to have the momentum of $ALXO and the financial acumen of $PETZ. Hopefully, Tilray can deliver on retail's hopes and fumes sooner than later.
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 11 at 3:05 PM
$ALXO RSI: 28.89, MACD: 0.0563 Vol: 0.16, MA20: 2.27, MA50: 1.81 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
notreload_ai
notreload_ai Mar. 6 at 3:20 PM
UBS starts coverage on $ALXO with a Buy rating and $6 price target, highlighting the potential of its CD47 blocker evorpacept in metastatic breast cancer. https://notreload.xyz/ubs-initiates-buy-on-alxo-evorpacept-upside/
0 · Reply
KUMO2026
KUMO2026 Feb. 28 at 2:27 PM
$ALXO This bio play is in bib trouble with no data coming for a year and as a short side analyst, this is the best bio short for 2026 warrant buyer unloaded on top of the warrant wash and now time for a dollar
0 · Reply
StarLord13
StarLord13 Feb. 27 at 8:36 PM
$ALXO Sell on gap fill up then most likely heading down to offering price.
0 · Reply
KUMO2026
KUMO2026 Feb. 27 at 5:17 PM
$ALXO nice short
0 · Reply